EKF Diagnostics Holdings plc (AIM: EKF ), has declared the distribution of shares in its investment, Trellus Health Limited ("Trellus").
The approval for the Dividend in Specie was granted by shareholders at the General Meeting held on 10 December 2020, to distribute the Company's entire holding of A Ordinary Shares in Trellus ("A Shares") by way of a dividend in specie to EKF Shareholders on the register at 17 December 2020.
EKF's investment in Trellus comprises 27,999,999 A Shares of £0.0001 each and 1 golden share of £0.0001 (the "Golden Share").
The Golden Share is the voting share in the capital of Trellus and will be retained by the Company.
Shareholders on the EKF register as at close of business on 17 December 2020 will receive one A Share for every 16.25 ordinary shares held in the Company.
Relevant EKF Shareholders will receive a letter informing them of their beneficial holdings of Dividend Shares shortly after the transfer of the Dividend Shares to Broadway.
To learn more about Trellus Health, watch the CEO Monique Fayad and Co-Founder Marla Dubinsky explain how this pioneering, resilience driven digital healthcare provider plans to revolutionise the future treatment of complex chronic diseases, such as Inflammatory Bowel Diseases, Crohns and ulcerative colitis:
